Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive
ORGANISM(S): Amycolatopsis Mediterranei S699
SUBMITTER: RUP LAL
LAB HEAD: Rup Lal
PROVIDER: PXD016416 | Pride | 2021-03-11
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
20171031_OP_DU_AM_13_1.raw | Raw | |||
20171031_OP_DU_AM_13_2.raw | Raw | |||
20171031_OP_DU_AM_13_3.raw | Raw | |||
20171031_OP_DU_AM_13_4.raw | Raw | |||
20171031_OP_DU_AM_17_1.raw | Raw |
Items per page: 1 - 5 of 48 |
Journal of proteomics 20210302
Rifamycin B is produced by Amycolatopsis mediterranei S699 as a secondary metabolite. Its semi-synthetic derivatives have been used for curing tuberculosis caused by Mycobacterium tuberculosis. But the emergence of rifampicin-resistant strains required analogs of rifamycin B to be developed by rifamycin biosynthetic gene cluster manipulation. In 2014 genetic engineering of the rifamycin polyketide synthase gene cluster in S699 led to a mutant, A. mediterranei DCO#34, that produced 24-desmethylri ...[more]